Chimerix (CMRX) Competitors

Arcutis Biotherapeutics (NASDAQ:ARQT) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, community ranking, valuation, institutional ownership and profitability.

Which has more risk and volatility, ARQT or CMRX?

Arcutis Biotherapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.

Does the media refer more to ARQT or CMRX?

In the previous week, Chimerix had 30 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 33 mentions for Chimerix and 3 mentions for Arcutis Biotherapeutics. Chimerix's average media sentiment score of 0.60 beat Arcutis Biotherapeutics' score of 0.25 indicating that Chimerix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Chimerix	10 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, ARQT or CMRX?

Chimerix has lower revenue, but higher earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$138.71M	10.97	-$262.14M	-$1.79	-7.26
Chimerix	$320K	1,447.47	-$82.10M	-$0.94	-5.48

Is ARQT or CMRX more profitable?

Chimerix has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Chimerix's return on equity of -50.78% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-140.97%	-119.11%	-45.95%
Chimerix	N/A	-50.78%	-44.94%

Do insiders & institutionals have more ownership in ARQT or CMRX?

45.4% of Chimerix shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 13.1% of Chimerix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts rate ARQT or CMRX?

Arcutis Biotherapeutics currently has a consensus target price of $16.60, indicating a potential upside of 27.68%. Chimerix has a consensus target price of $9.00, indicating a potential upside of 74.76%. Given Chimerix's stronger consensus rating and higher possible upside, analysts clearly believe Chimerix is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Chimerix	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in ARQT or CMRX?

Chimerix received 333 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. However, 65.63% of users gave Arcutis Biotherapeutics an outperform vote while only 63.97% of users gave Chimerix an outperform vote.

Company	Underperform	Outperform
Arcutis Biotherapeutics	Outperform Votes 63 65.63%	Underperform Votes 33 34.38%
Chimerix	Outperform Votes 396 63.97%	Underperform Votes 223 36.03%

Summary

Chimerix beats Arcutis Biotherapeutics on 14 of the 18 factors compared between the two stocks.